Peptides · Peptide comparison
Setmelanotide vs Tirzepatide
Targeted MC4R agonist for rare genetic obesity caused by melanocortin pathway defects
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Weight Management
Metabolic Health
Quality of Life
Weight Loss
Appetite Control
Blood Sugar Control
Technical data
Compound specifications
Setmelanotide
- Molecular formula
- C49H68N18O9S2
- Molecular weight
- 1,117.3 Da
- Half-life
- ~11 hours
- Bioavailability
- ~79% subcutaneous bioavailability
- CAS number
- 920014-72-8
Tirzepatide
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.45 g/mol
- Half-life
- Approximately 5 days (120 hours)
- Bioavailability
- ~80% (subcutaneous)
- CAS number
- 2023788-19-2
Protocols
Dosing compared
Setmelanotide
Subcutaneous
- First 2 weeks2 mgOnce daily · First 2 weeksFDA Imcivree starting dose for BBS or POMC/PCSK1/LEPR-deficiency obesity in patients 2 years and older; injected on waking [6]. (Acquired hypothalamic obesity starts lower at 0.5 mg daily.)
- Ongoing maintenance3 mgOnce daily · Ongoing maintenanceRecommended maintenance/maximum dose after tolerating 2 mg for 2 weeks; first approval and pivotal trials [1][6]. Effective for MC4R-pathway and hypothalamic obesity [2][3].
Tirzepatide
Subcutaneous injection
- First 4 weeks2.5 mgOnce weekly · First 4 weeksFDA label starting dose; non-therapeutic, used only to improve GI tolerability before escalating [5]. Inject in abdomen, thigh, or upper arm and rotate sites.
- Increase by 2.5 mg after at least 4 weeks at each dose5-10 mgOnce weekly · Increase by 2.5 mg after at least 4 weeks at each dosePer FDA label, increase to 5 mg after 4 weeks; further increases in 2.5 mg steps no sooner than every 4 weeks as needed [5].
- Ongoing maintenance12.5-15 mgOnce weekly · Ongoing maintenance15 mg is the maximum FDA-labeled dose [5]. SURMOUNT-1 used up to 15 mg weekly for obesity [1].
Applications
Best suited for
Setmelanotide
- Treating obesity caused by confirmed POMC deficiency mutations
- Setmelanotide is particularly well-suited for individuals focused on treating obesity caused by confirmed pomc deficiency mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
- Managing obesity from PCSK1 or LEPR genetic defects
- Setmelanotide is particularly well-suited for individuals focused on managing obesity from pcsk1 or lepr genetic defects. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Setmelanotide is particularly well-suited for individuals focused on reducing hyperphagia and body weight in bardet-biedl syndrome. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
- Addressing early-onset severe obesity with identified melanocortin pathway mutations
- Setmelanotide is particularly well-suited for individuals focused on addressing early-onset severe obesity with identified melanocortin pathway mutations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2].
Tirzepatide
- People Who Want Maximum Weight Loss Results
- If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close [1].
- Those Who Haven't Succeeded with Semaglutide
- Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss [2][9].
- People with Type 2 Diabetes Needing Aggressive Control
- Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health [2].
- Individuals Looking to Transform Their Relationship with Food
- Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you [11].
Safety profile
Side effects
Setmelanotide
Common
- Skin Hyperpigmentation
- Injection Site Reactions
- Nausea
- Diarrhea
Uncommon
- Hair Color Darkening and Nevus Changes
Serious
- Depression and Suicidal Ideation
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research status
Safety & evidence
Setmelanotide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Setmelanotide demonstrates favorable tolerability in Phase 3 trials with safety data from over 200 patients across POMC, PCSK1, LEPR-deficient, and Bardet-Biedl syndrome populations. The most common adverse effect is dose-dependent skin hyperpigmentation (>60% of patients) [6] due to off-target MC1R activation on melanocytes—a manageable, reversible pharmacological effect rather than true toxicity. [6] Serious psychiatric adverse events including depression and suicidal ideation require baseline mental health screening and ongoing monitoring in all patients [6].
Contraindications
- Known hypersensitivity to setmelanotide or any excipients [6]
- Obesity not caused by POMC, PCSK1, or LEPR deficiency, Bardet-Biedl syndrome, or acquired hypothalamic obesity [6]
- Suspected POMC, PCSK1, or LEPR deficiency where the gene variants are classified as benign or likely benign (BBS and acquired hypothalamic obesity need no genetic test) [6]
Tirzepatide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. [1][2][3] The FDA approved it after thorough safety review. [5][6] While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. [5][6] Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes. [16]
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC) [6]
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [6]
- History of serious allergic reaction to tirzepatide [6] or any GLP-1/GIP medication
Decision guide
Which is right for you?
Setmelanotide
Choose Setmelanotide if…
- Treating obesity caused by confirmed POMC deficiency mutations
- Managing obesity from PCSK1 or LEPR genetic defects
- Reducing hyperphagia and body weight in Bardet-Biedl syndrome
- Addressing early-onset severe obesity with identified melanocortin pathway mutations
Tirzepatide
Choose Tirzepatide if…
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement